Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Promising cellular therapies emerging in multiple myeloma

Peter Voorhees • 30 Sep 2022
SOHO 2022
Multiple Myeloma CAR-T NK-Cell Therapy

Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, shares some insights into promising cellular therapies emerging in multiple myeloma, including allogeneic CAR-T cells, natural killer (NK) cell therapies, and dual-targeting CAR-T cell products. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Peter Voorhees

4:15
Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
Peter Voorhees • 30 Sep 2022
2:39
The role of tandem transplantation in multiple myeloma & how this may be impacted by novel agents
Peter Voorhees • 30 Sep 2022
4:51
The current frontline treatment strategy in multiple myeloma
Peter Voorhees • 30 Sep 2022
2:31
Stem cell collection in patients with multiple myeloma treated with anti-CD38 monoclonal antibodies
Peter Voorhees • 13 Dec 2021

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals